In human immunodeficiency virus type 1 (HIV-l)-infected adults, the proportion of gpl20-free CD4 moleculeson the surface of T lymphocyteswas measured by double-epitopeEIA and expressed as a CD4 epitope concentration ratio. In 51% of these patients (n = 81), CD4 T cells showed a significant decrease (up to 100%) in the accessibility of the CD4 epitope corresponding to the gp120 binding site (CDR2-like region), whereas another epitope in the Dl domain remained accessible. Of interest, a significant increase in the CD4 gp120 binding site concentration, without a change in T cell counts, was observed within 10 days after initiation of zidovudine treatment. Furthermore, CD4 masking by gp120 was associated with a poor clinical patient status. The assessment of the CD4 epitope concentration ratio is proposed as a surrogate marker of disease progression in HIV-1-infected patients.
The CD4 membrane glycoprotein serves as the cell surface receptor for the human immunodeficiency virus type 1 (HIV-1) through its interaction with the HlV-I 120-kDa envelope glycoprotein (gpI20) [1, 2] . The primary gp120 binding site is in a region homologous to CDR2 of the immunoglobulin light chain [3] [4] [5] [6] within the first domain (D!) of the CD4 molecule and involves residues from 40 to 59. During the clinically latent stages of HIV-I disease, large numbers of infected cells in lymph nodes and high levels of HIV-1 particles in plasma have been detected [7] [8] [9] , suggesting that T cells are in general heavily exposed to viral gp 120. Qualitative analysis has shown that peripheral lymphocytes are covered with gpl20/anti-gpl20 complexes [10] in association with complement [11] or with antiidiotypic antibodies mimicking gpl20 [12] .
We previously investigated the CD4 CDR2-like region masking on T cells from HIV-1-seropositive patients by adapting the highly sensitive CD4/CD8 immunoassay (CAPCEL-LIA; Sanofi Diagnostics Pasteur, Mames-La-Coquette, France) [13, 14] for the quantitative determination of two distinct epitopes of the CD4 molecule [15] . Here we compare the CD4 epitope concentration ratio (ECR), which represents the propor-tion of gpl20-free CD4, with other markers of HIV-l disease progression in humans: clinical status as expressed by the Karnofsky index (KI), p24 antigenemia, CD4 cell counts, and programmed cell death (PCD) of CD4 cells.
Methods
Blood samples and patients. Venous blood was drawn into 5-mL tubes containing EDTA and analyzed within 6 h. Fifty HIV-l-seronegative adults served as controls. Study subjects were 81 HIV-1-infected patients seen at the Department of Infectious Diseases, Centre Hospitalier Universitaire (MontpelIier, France). Their clinical (A, B, and C) and biologic (1, 2, and 3) categories were defined according to the 1993 revised CDC classification system for HIV infection [16] . Nine patients were asymptomatic (2 in class Al and 7 in class A2), 20 had AIDS-related complex (5 in class Bl and 15 in class B2), and 52 had AIDS (4 in class A3, 24 in class B3, 1 in class Cl, 3 in class C2, and 20 in class C3).
CAPCELLIA. With this assay, we determined the concentration of CD4 or CD8 molecules expressed on the surface of T lymphocytes. Briefly, peripheral blood mononuclear cells (PBMC) were separated from blood by Ficoll-Paque densitygradient centrifugation (Pharmacia, Uppsala, Sweden). T cells from PBMC suspension were simultaneously immunocaptured in a microtiter plate via the C02 antigen and allowed to react with the peroxidase-labeled anti-CD4 monoclonal antibody (MAb) (or anti-CD8 MAb) for 20 min at room temperature. To determine the CD4 (or CD8) concentrations, absorbances of assays were compared to standards that consisted of cells of the Ichikawa line, previously calibrated by the Scatchard technique using radiolabeled antibodies [13] . To assess CD4 lID 1996;173 (March) epitope masking on T cells incubated in the presence of gpl20 or on T cells from HIV-1-infected patients, we used a doubleepitope configuration of the CAPCELLIA. In this configuration, one labeled CD4 MAb (FIOI-69) detected only gp120-free CD4 molecules, and the other labeled CD4 MAb (BF5) detected all CD4 molecules, either free or complexed with gp120. Results of the double-epitope CAPCELLIA allowed us to calculate the ECR of gpl20-free membrane CD4 to total membrane CD4.
Incubation ofcells with recombinant gp120. CD4-positive Ichikawa cells (0.5 X 10 9 cellslL) or PBMC (l09 cellslL) were cultured in RPMI 1640 supplemented with 10% fetal calf serum (FCS) and antibiotics (100 IV/mL penicillin and 100 j.tg/mL streptomycin). Recombinant gpl20 (American Bio-Technologies, Cambridge, MA), a 120-kDa HIV-I envelope glycoprotein, was added to the medium at concentrations of 0.075-10 j.tg/mL. After incubation for 3 h to 4 days at 37°C, CD4 and CDS molecules (controls) were assayed using 1 X 10 4 or 3 X 10 4 Ichikawa cells or PBMC, respectively. In some experiments, sera from HIV-1-infected patients were added to cells previously incubated with gpl20 at 37°C.
RIA ofCD4 or gp120 molecules on the cell surface. Direct determination of antigen was done by using J25I_labeled MAb FIOI-69 or MAb BF5 (both anti-CD4) or MAb 110-4 (antigpI20). MAbs (50 j.tg) were labeled with 1 mCi of J25INa (Arnersham, Les VIlis, France) in the presence of chloramine-T. After incubation for 1 min, the reaction was stopped by addition of sodium metabisulfite. Free 125 1 was removed by chromatography on a PD-lO Sephadex G-25M column (Pharmacia). Fractions that contained labeled MAbs were pooled, and radioactivity was measured on an autogamma counter (MDA 312; Kontron, St. Quentin-en-Yvelines, France). Ichikawa cells or PBMC were preincubated with gpl20 for different periods. Then CD4 was assayed using either of the two 125I-labeled MAbs (150 X 10 3 cprnlwell corresponding to 5 ng of MAb/mL [3 X 10 4 cells/well]) and incubated at room temperature for 20 min. After four washes, cell-associated radioactivity was determined in triplicate in a counter. Nonspecific binding was done on cell-free wells.
Preparation of sera from HIV-1-infected patients. Sera were first absorbed with CD4 T cells of the CEM line (l 0 7 cells/mL serum, 12 h at 4°C), centrifuged at 600 g for 20 min, and added (1/100 final dilution) to PBMC previously incubated with gp120. The anti-gpl20 activity of the sera was assessed by Western blot analysis, and the binding of antibodies to CD4 cells exposed to gpl20 was analyzed by flow cytometry using a fluorescein isothiocyanate (FITC)-Iabeled anti-human immunoglobulin antibody (Immunotech, Marseille, France).
Flow cytometry. The number of CD4 cells per microliter of blood was determined as the product ofthe absolute lymphocyte counts and percentages of the CD4 cell subset. Percentages were determined by flow cytometry (FACStar; Becton Dickinson Immunocytometry systems, San Jose, CA). The T lymphocyte population was characterized by two-color immunofluorescence with MAbs to CD4 in conjunction with MAb to CD3 (Leu-3a-phycoerythrin [PE], MAb specific for CD4 domain Dl , and Leu-4-FITC, MAb specific for CD3; Becton Dickinson). To detect T cell-associated gpI20/anti-gpI20 antibody complexes, PBMC from 6 controls and IS HIV-l-positive patientswere analyzed by the simultaneous two-colorimmunofluorescence method. Cells were incubated with PE-conjugated anti-CD4 Leu-3a(BectonDickinson) or PE anti-CDS (Immunotech) and FITC-Iabeled sheepanti-gpl20 (Aalto, Dublin)or FITC-conjugated goat anti-human immunoglobulin (Immunotech).
PCD of CD4 cells. Enriched CD4 cell preparations were obtained by negative selection of PBMC suspensions from 6 controls and 9 HIV-1-infected patients. CDS or CD19 lymphocytes and CD14 monocytes were removed by immunomagnetic separation after incubation with MAbs (Immunotech), then incubated with anti-mouse IgG-coated immunomagnetic beads (Dynabeads; Dynal, Oslo). Enriched CD4 cells (>90% as controlled by flow cytometry) were cultured 2 days at 37°C in RPMI 1640 supplemented with 10% FCS and anti-TcR antibody (BMA-031, 10 j.tg/mL; Behring Diagnostic, Rueil-Malmaison, France). Percentages of apoptotic cells, determined on 2 X 10 2 cells, were assessed by exclusion of 0.1% trypan blue. Typical apoptotic patterns were confirmed by electron microscopy.
HIV p24 antigen detection. The p24 antigen assay (Coulter, Hialeah, FL) was used to quantify HIV-l antigen in plasma after acid dissociation of immune complexes [17] . The results were considered positive when the antigen concentration was >30 pg/mL.
Clinical status of HIV-1-infected patients. We used the KI to quantify the physical activity and the clinical status of patients. Patients with KIs >SO or~SO were considered to have good or poor clinical status, respectively.
Statistical analysis. We compared the ECRs with KIs and p24 antigen concentrations or CD4 cell counts for each patient by X 2 test (RSI software; BBN, Cambridge, MA). P~.05 was considered statistically significant.
Results

Zidovudine-dependent increase of CD4 concentration in blood samples from HIV-1-infected patients.
To determine the concentration of gpl20-free CD4 molecules expressed on the surface of T cells from HIV-1-infected patients, we used the CAPCELLIA, in which the peroxidase-labeled anti-CD4 MAb and gpl20 interact with the same site on the CD4 molecule and therefore compete for binding [13, IS] . In a followup of 6 HIV-1-infected patients treated with zidovudine, we found a significant increase in CD4 cell concentrations (4.3 ± 2.1 pM before treatment vs. S.7 ± 3.3 pM after treatment). In patients 3, 4, and 5, monitored during the early period of treatment, these changes in CD4 cell concentrations were not accompanied by a parallel increase in numbers of CD4 cells determined by conventional CD4 cell enumeration (figure 1). .e: 8 ..e: [18] ; latter amino acid is strongly involved in gpl20 binding [6, 18] ). Labeled MAb FIOI-69 detects only gp120-free CD4 molecules [13] . Other epitope in Dl domain is recognized by MAb BF5, which is directed against site distinct from CDR2-like region (Piatier-Tonneau D, personal communication). Labeled MAb BF5 detects all CD4 molecules (complexed to ligand or not). B, Validation of double-epitope CD4 immunoassay. Ichikawa cells (10 6 cells/mL in RPMI 1640) were incubated with recombinant gpl20 (0.075-5 tJ.g/mL for 3 h at 20°C). Specific binding of gpl20 was assayed with labeled anti-gpl20 MAb 110-4, which binds to epitope not directly involved in CD4 binding [19] . Gpl20 binding was expressed as % of cell surface gpl20 molecules detected by comparison with gpl20 bound under saturating conditions (5 fLg/mL). Error bars show SD of mean of triplicate experiments.
In these patients, this increase in the CD4 concentration after only 10 days of treatment, without a change in the CD4 cell number, suggests unmasking of the CDR2-like region hitherto complexed with gp120.
Validation of the CD4 double-epitope assay on cells incubated with gp120. To measure the proportion of gpl20-free CD4 molecules, we developed a double-epitope ErA of CD4 [15] ( figure 2A) . The experimental validation of this immunoassay was done using CD4 cells of the Ichikawa line preincubated in the presence of soluble recombinant gp120, followed by addition of one of the labeled anti-CD4 MAbs (figure 2B).
Using labeled MAb FIOI-69, a decrease in the number of gpl20-free CD4 molecules was observed; for example, only 50% of the CD4 molecules were detected (control without gpl20 = 100%) with gpl20 at 1.25 j1.g/mL culture medium. In contrast, when the labeled MAb BF5 was used, the number of CD4 molecules detected remained unchanged regardless of the gpl20 concentration in the medium. These results indicate that the CD4 epitope recognized by MAb FIOI-69 is masked by gpl20 and that the CD4 epitope recognized by MAb BF5 is independent of the gpl20-binding site. The quantitative comparison between the number of gpl20 molecules detected on t Assayed using anti-CD4 MAb BF5, which is directed against site distinct from gpl20 binding site.
the cell surface and the corresponding decrease in the number of gpl20-free CD4 molecules showed that the loss of accessibility of CD4 molecules corresponded to the binding of gpl20 to CD4.
When PBMC from healthy subjects were incubated with different concentrations of gpl20 for 2 days at 37°C, a gp120-dependent CD4 decrease was found by using either anti-CD4 MAb FIOI-69 (which detected only gp120-free CD4 molecules) or MAb BF5 (which detected all CD4 molecules free or complexed with gpl20 [table 1]). However, the CD4 molecules assayed using MAb BF5 never completely disappeared, even in the presence of a gp 120 concentration as high as 10 flg/mL (data not shown). Thus, the decrease in signal given by MAb BF5 depended only on gpl20-induced modulation of CD4, whereas the decrease in signal given by MAb FlO1-69 resulted from gpl20-induced modulation of CD4 and gpl20-masking of the FIOI-69 MAb epitope on CD4. As a consequence, we propose defining an ECR of gpl20-free membrane CD4 to total membrane CD4. The ECR values obtained on PBMC incubated at 37°C decreased when the concentration of added gpl20 increased (table I). Figure 3 shows that the gpl20-dependent CD4 decrease led to almost stable CD4 levels during 1-4 days of culture of PBMC at 37°C in the presence of a fixed concentration of gp120, whereas the CD4 molecules remained unchanged in control cells incubated under the same conditions but in the absence of gp120. The addition of serum with a high titer of anti-gpl20 Ig for 1 h at 4°C to cells did not modify the ECR of PBMC suspensions (data not shown), suggesting that the double-epitope assay of CD4 molecules could be efficiently used to study T cells from HIV-1-positive patients.
Determination ofthe ECR in HIV-l-infected patients: comparison with HIV infection progression markers.
We next determined the ECRs of T cells from healthy subjects (n = 50) and from patients (n = 81) in CDC classifications A-C (figure 4). While all seronegative subjects had normal ECRs (1.0 ± 0.12), the number of patients with an ECR~0.8, the cutoff value of controls, increased as a function of the severity of the disease (23%, 43%, and 79% for categories A, B, and C, respectively). In some patients in categories Band C, the complete loss of the FIOI-69 epitope was associated with persistence of the BF5 epitope (ECR = 0). For a few patients with low ECRs, after separation of PBMC from blood, cells were washed twice then incubated in complete RPMI 1640 (10 mL) with gentle stirring (3 h at 20°C in a 50-mL culture bottle). Under these conditions, we observed an increase in ECRs (0.38 ± 0.10 vs. 0.70 ± 0.14 before and after washing, respectively, n = 5), indicating an increase in the accessibility of the CDR2-like region. These findings suggest either dissociation of the CD4-ligand complexes or down-modulation of these complexes followed by reexpression of ligand-free CD4 molecules.
In an attempt to identify the ligand involved in in vivo masking of the CDR2-like region, we analyzed PBMC suspensions from patients by simultaneous two-color immunofluorescence flow cytometry method. While CD4 cells from 6 non- infected subjects and 10 HIV-1-infected patients with ECRs >0.80 were negative for the presence of gp120 or IgG, CD4 cells from 8 patients with ECRs~0.80 (0.40 ::t::: 0.12) showed double positivity: gp120/CD4 and IgG/CD4 (94.6% ::t::: 4.5%; P = .01). In contrast, gp120/CD8 and IgG/CD8 were 4.2% :!:: 6.2%. No CD4 cells with an ECR~0.80 had only IgG without gp120, suggesting that the IgG associated with T cells was directed against gp120. We next assessed the relationship between ECRs and clinical status (expressed by the KI) and p24 antigenemia. We found a significant relationship between the ECR and the KI (P = .001, n = 79; figure 5A ) and a significant association between ECR and p24 antigenemia (P = .001, n = 65; figure 5B). The relationship between the absolute CD4 cell counts (threshold value = 410 X 106/L blood corresponding to the lower cell count limit for 95% of normal subjects [20] ) and the Kl was also significant (P = .019, n = 66; figure 5C ). This difference in statistical significance suggests that the ECR and p24 antigenemia are more predictive than CD4 cell counts of the clinical status of HIV-I-infected patients. In particular, in the subpopulation of patients with low CD4 cell counts (50-200 cells/ pL), the ECR permitted differentiation between patients with good and poor clinical status. All patients with an ECR of 1. Finally, we analyzed the PCD [21] [22] [23] of enriched CD4 cells obtained by negative immunomagnetic separations of PBMC. PCD was analyzed by trypan blue exclusion and electron microscopy after 2 days at 37°C in RPMI 1640 supplemented with 10% FCS. Only 2.9% :!:: 1.07% of the CD4 cells from 6 controls (ECR = 1.05 :!:: 0.14) showed spontaneous cell death but without morphologic hallmarks of apoptosis; in contrast, 16.8% :!:: 7.25% of the CD4 cells from 7 Hl'V-1-infected patients with an abnormal ECR (0.49 :!:: 0.15) showed spontaneous cell death with typical morphology of apoptosis, including dense crescents or clusters of chromatin near the nuclear envelope. CD4 cells from 2 other Hlv-Iv-infected patients with normal ECRs (0.85 and 1.05, respectively) had low PCD (1.8% and 4.1%, respectively). The relationship between the ECRs and the percentages of apoptotic cells in mv-1-infected patients was highly significant (r = .76, P = .01 [n = 9]; table 2). These findings are consistent with the presence of gp120/anti-gp120 antibody complexes on the CD4 lymphocytes from these HfV-1-infected patients. In contrast, no significant correlation was observed between CD4 cell counts and apoptotic cells (r = .04). These findings suggest that the ECR is a predictive marker of PCD of CD4 cells.
Discussion
The CAPCELLIA developed in our laboratory was first used to determine the gpl20-free CD4 concentrations in blood of mv-1-infected patients being treated with zidovudine. In some patients, an unexpected finding after zidovudine treatment was an increase in the gpl20-free CD4 concentrations that was not accompanied by a parallel increase in the number of CD4 cells. This discrepancy between the immunoassay data and the CD4 cell counts can be explained by the fact that, in flow cytometry, a cell is determined as CD4-positive regardless of the intensity of the immunofluorescence above a fixed thresh- . .
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• .. old, whereas every CD4 molecule accessible to the labeled antibody is assayed in the ELISA. These findings suggest a potential FlO 1-69 epitope masking by gp 120 in HIV-1-infected patients and unmasking of this epitope early after initiation of zidovudine treatment. This rapid zidovudine-dependent unmasking of the CD4 epitope is consistent with the marked decrease in plasma virus after I week of zidovudine treatment [9] and the increase in the mean number of available CD4 receptors per cell after 30 days of treatment [24] . We next attempted to determine the proportion of gp120-free CD4 molecules by using a double-epitope configuration of the CAPCELLIA. This CD4 EIA allows determination ofthe ratio of the concentrations of two CD4 epitopes. The efficacy of the assay in analyzing the loss of the CD4 CDR2-like region and the gp120-dependent CD4 down-modulation was shown by decreased ECRs for viable T cells incubated at 37°C in the presence of soluble recombinant gp120. Abnormally low ECRs (i.e., below the 0.8 threshold) were observed in 51% of blood samples from HIV-1-infected patients, suggesting the presence of soluble or virus-associated gp120 on the cell surface. The low ECRs of the CD4 cells we observed in vivo and in vitro are consistent with the decrease in the number of CD4 receptors observed with MAb Leu-3a in HIV-infected patients [10, 24, 25] and the emergence of a population of MAb T4-negative, MAb OKT4-positive cells in HIV-infected T cell cultures [26) . We observed a similar CD4 epitope profile (i.e., MAb F101-69-negative, MAb BF5-positive) for both PBMC incubated with soluble gp120 and PBMC from HIV-1-infected patients. In these cases, in which ECR = 0, the concentrations of CD4 determined with MAb BF5 corresponded to numerous T cells that could not be detected by EIA or flow cytometry [15] when MAb F101-69 or other MAbs specific for the CD4 gp120 site are used [18) . It follows that CD4 cell numbers determined by flow cytometry would clearly result in an overestimation of CD4 lymphocyte turnover in HIV-1-infected patients treated with antiretroviral drugs [27] [28] [29] ; indeed, before treatment, a cell whose CD4 molecules are masked by HIV particles or soluble noninfectious gp120 will be first considered as CD4-negative and may become positive after treatment, appearing then falsely as a "new cell."
Finally, we showed a significant correlation between the ECRs and the KIs, HIV-p24 antigenemia, CD4 cell numbers, and PCD (apoptosis) of CD4 cells from HIV-1-infected patients. These results suggest that the ECR is indeed a potential marker of HIV-1 disease progression.
In conclusion, the gp l20-dependent ECR decrease, which appears linked to poor clinical status, probably corresponds to an important and critical stage of disease progression, when the immune system loses its capacity to control viral gp120 production through blocking antibodies, allowing massive complexation ofCD4 with gp120. The presence of these complexes probably leads to permanent impairment of T cell function by blocking CD4-HLA class II interactions [30, 31] and to uncontrolled progression of immunopathogenic mechanisms such as anergy [32] and PCD. Since the determination of the CD4 cell counts fails to efficiently predict progression of HIV-1 disease [33] , we propose the determination of the CD4 ECR as a surrogate marker to assess this particularly critical stage of HIV-1 infection.
